Comparative Pharmacology
Head-to-head clinical analysis: THIOTHIXENE versus TRIFLUOPERAZINE HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIOTHIXENE versus TRIFLUOPERAZINE HCL.
THIOTHIXENE vs TRIFLUOPERAZINE HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the brain. It also has alpha-adrenergic and histamine H1 blocking activity, with minimal anticholinergic effects.
Trifluoperazine is a typical antipsychotic of the phenothiazine class. It acts primarily as a dopamine D2 receptor antagonist, blocking postsynaptic dopamine receptors in the mesolimbic and mesocortical pathways. It also exhibits moderate anticholinergic, antiadrenergic, and antihistaminergic activity.
Initial: 2 mg orally three times daily; maintenance: 5-30 mg/day orally in divided doses; maximum: 60 mg/day. IM: 4 mg 2-4 times daily; maximum 30 mg/day.
2-10 mg orally twice daily; maximum 40 mg/day. For severe psychosis, 5-20 mg intramuscularly every 4-6 hours, maximum 30 mg/day.
None Documented
None Documented
Clinical Note
moderateThiothixene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Thiothixene."
Clinical Note
moderateThiothixene + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone propionate."
Clinical Note
moderateThiothixene + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Thiothixene."
Clinical Note
moderateTerminal half-life: 10-20 hours (mean ~14 h). Clinical context: Steady-state achieved in ~2-3 days; allows once-daily dosing for maintenance.
12-30 hours (terminal elimination half-life); clinical context: requires multiple daily dosing or extended-release formulations for steady-state maintenance.
Primarily renal: 65-70% as metabolites, <1% unchanged. Fecal: 15-20% via biliary elimination.
Renal (as metabolites, less than 1% unchanged); fecal (biliary) elimination of metabolites accounts for a significant portion; total recovery in urine and feces accounts for >90% of a dose.
Category C
Category A/B
Typical Antipsychotic
Typical Antipsychotic
Thiothixene + Methylphenidate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate."